On May 12, 2025, President Trump signed an executive order directing the Secretary of HHS to set and communicate most-favored-nation (“MFN”) price targets to manufacturers and propose a rulemaking plan to impose MFN pricing if “significant progress” is not made, and also directing the federal government to support regulatory paths to allow direct-to-patient sales for companies that meet these targets.
All entries for: CERO THERAPEUTICS HOLDINGS, INC.
November 19, 2025
CERO THERAPEUTICS HOLDINGS, INC.
Negative Outlook
Scottsdale, AZ
51-200 employees
For example, the Medicare Drug Price Negotiation Program, administered by CMS as part of the Inflation Reduction Act of 2022, commonly referred to as the IRA, may apply to our products if they are selected for negotiation, which could materially reduce the amount of revenue we can generate from our products if they are approved.
Disease Area: Oncology
Drug Type: Biologic
August 22, 2025
CERO THERAPEUTICS HOLDINGS, INC.
Negative Outlook
Scottsdale, AZ
51-200 employees
For example, the Medicare Drug Price Negotiation Program, administered by CMS as part of the Inflation Reduction Act of 2022, commonly referred to as the IRA, may apply to our products if they are selected for negotiation, which could materially reduce the amount of revenue we can generate from our products if they are approved.
Disease Area: Oncology
Drug Type: Small Molecule